117 related articles for article (PubMed ID: 36993676)
21. French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study.
Garnham A; Bruon F; Berthon C; Lebon D; Parimi M; Polya R; Makhloufi KM; Dramard-Goasdoue MH
Oncol Ther; 2023 Sep; 11(3):375-389. PubMed ID: 37578642
[TBL] [Abstract][Full Text] [Related]
22. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
23. Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies.
Griffioen MS; de Leeuw DC; Janssen JJWM; Smit L
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884517
[TBL] [Abstract][Full Text] [Related]
24. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.
Tsuzuki H; Kawase T; Nakazawa T; Mori M; Yoshida T
Oncotarget; 2022 Dec; 13():1359-1368. PubMed ID: 36537913
[TBL] [Abstract][Full Text] [Related]
26. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
27. FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia.
Fang DD; Zhu H; Tang Q; Wang G; Min P; Wang Q; Li N; Yang D; Zhai Y
Transl Oncol; 2022 Jan; 15(1):101244. PubMed ID: 34710737
[TBL] [Abstract][Full Text] [Related]
28. Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions.
Fedorov K; Maiti A; Konopleva M
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190240
[No Abstract] [Full Text] [Related]
29. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
30. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
Zeng Z; Maiti A; Herbrich S; Cai T; Cavazos A; Manzella T; Ma H; Hayes K; Matthews J; DiNardo CD; Daver NG; Konopleva MY
Cancer; 2023 Feb; 129(4):531-540. PubMed ID: 36477735
[TBL] [Abstract][Full Text] [Related]
31. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
32. Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.
Sexauer AN; Tasian SK
Front Pediatr; 2017; 5():248. PubMed ID: 29209600
[TBL] [Abstract][Full Text] [Related]
33. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract][Full Text] [Related]
34. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Schneider P; Nollau P; Horstmann M; Beverloo HB; van der Voort E; Valsecchi MG; de Lorenzo P; Sallan SE; Armstrong SA; Pieters R
Blood; 2005 Oct; 106(7):2484-90. PubMed ID: 15956279
[TBL] [Abstract][Full Text] [Related]
35. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Weisberg E; Liu Q; Nelson E; Kung AL; Christie AL; Bronson R; Sattler M; Sanda T; Zhao Z; Hur W; Mitsiades C; Smith R; Daley JF; Stone R; Galinsky I; Griffin JD; Gray N
Leukemia; 2012 Oct; 26(10):2233-44. PubMed ID: 22469781
[TBL] [Abstract][Full Text] [Related]
36. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.
Grundy M; Balakrishnan S; Fox M; Seedhouse CH; Russell NH
Oncotarget; 2018 Dec; 9(102):37777-37789. PubMed ID: 30701031
[TBL] [Abstract][Full Text] [Related]
37. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.
Novotny-Diermayr V; Hart S; Goh KC; Cheong A; Ong LC; Hentze H; Pasha MK; Jayaraman R; Ethirajulu K; Wood JM
Blood Cancer J; 2012 May; 2(5):e69. PubMed ID: 22829971
[TBL] [Abstract][Full Text] [Related]
38. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
39. Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella A; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Expert Opin Emerg Drugs; 2022 Mar; 27(1):1-18. PubMed ID: 35076348
[TBL] [Abstract][Full Text] [Related]
40. Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia.
Yang C; Gu Y; Ge Z; Song C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]